AstraZeneca has reported positive “high-level” outcomes from the randomised Phase III MATTERHORN trial of Imfinzi (durvalumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback